Actively Recruiting
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Led by Barbara Ann Karmanos Cancer Institute · Updated on 2025-07-25
1020
Participants Needed
11
Research Sites
673 weeks
Total Duration
On this page
Sponsors
B
Barbara Ann Karmanos Cancer Institute
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV. Comprehensive genomic analysis may identify specific gene mutations (changes in deoxyribonucleic acid \[DNA\]) and help doctors to tailor treatment to target the specific mutations.
CONDITIONS
Official Title
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with stage IV or recurrent non-small cell lung cancer and have archival tissue or are willing to undergo biopsy for genomic analysis
- Zubrod performance status of 0 to 2
- Life expectancy of at least 3 months
- Absolute neutrophil count above 1.5 x 10^9/L
- Platelet count above 100,000 x 10^9/L
- Serum creatinine at or below 1.5 times the institutional upper limit of normal or creatinine clearance over 45 mL/min
- Serum bilirubin at or below 1.5 times the institutional upper limit of normal
- Transaminases (SGOT and/or SGPT) and alkaline phosphatase at or below 2.5 times institutional upper limit unless liver metastases are present and related to enzyme elevation
- Laboratory tests performed within 30 days before enrolling
- Tumor biopsy specimen obtained within 60 days before enrolling, not from a previously radiated tumor site, and no systemic therapy received since biopsy
- Signed informed consent according to institutional and federal guidelines
You will not qualify if you...
- Presence of concurrent malignancy unless unlikely to impact clinical outcome as judged by treating physician
- Serious medical illnesses such as uncontrolled congestive heart failure, uncontrolled angina, recent myocardial infarction or cerebrovascular event within 6 months, chronic active hepatitis, HIV infection, or active bacterial infection
- Pregnant or breastfeeding women
- Female patients of childbearing potential must use contraception and be informed about pregnancy-related trial limitations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
KCI at McLaren Bay Region
Bay City, Michigan, United States, 48708
Actively Recruiting
2
KCI at Mclaren Bloomfield Hills
Bloomfield Hills, Michigan, United States, 48302
Actively Recruiting
3
KCI At McLaren Clarkston
Clarkston, Michigan, United States, 48346
Actively Recruiting
4
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Actively Recruiting
5
KCI at McLaren Flint
Flint, Michigan, United States, 48532
Actively Recruiting
6
KCI at McLaren Greater Lansing, Mid Michigan Physicians
Lansing, Michigan, United States, 48910
Actively Recruiting
7
KCI at McLaren Lapeer Region
Lapeer, Michigan, United States, 48446
Actively Recruiting
8
KCI at McLaren Macomb
Mount Clemens, Michigan, United States, 48043
Actively Recruiting
9
KCI at McLaren Central Michigan
Mount Pleasant, Michigan, United States, 48858
Actively Recruiting
10
KCI at Northern Michigan
Petoskey, Michigan, United States, 49770
Actively Recruiting
11
KCI at McLaren Port Huron
Port Huron, Michigan, United States, 48060
Actively Recruiting
Research Team
G
Gerold Bepler, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here